Researcher:
Erbil, Damla

Profile Picture
ORCID

Job Title

Undergraduate Student

First Name

Damla

Last Name

Erbil

Name

Name Variants

Erbil, Damla

Email Address

Birth Date

Filters

2018 - 20193

Advanced Search

Filter by

Settings

Researcher Of Publications: search.filters.isAuthorOfPublication.2d482c49-59a1-4802-bf87-3e0359aebd67

Search Results

Now showing 1 - 3 of 3
  • Placeholder
    PublicationMetadata only
    A 70-year-old patient with seronegative lupus nephritis: rare case
    (Logos Tıp Yayıncılığı, 2018) N/A; N/A; N/A; N/A; N/A; N/A; Dağel, Tuncay; Meram, Ece; Önal, Emine Meltem; Erbil, Damla; Bülbül, Mustafa Cem; Uysal, Sanem Pınar; Doctor; Undergraduate Student; Undergraduate Student; Undergraduate Student; Researcher; Undergraduate Student; N/A; School of Medicine; School of Medicine; School of Medicine; School of Medicine; School of Medicine; Koç University Hospital; N/A; N/A; N/A; N/A; 327626; N/A
    Systemic lupus erythematosus (SLE) is an autoimmune disease known to be associated with various kinds of autoantibodies such as Antinuclear antibodies (ANA). ANA is found to be positive in most of the SLE patients. In fact, ANA positivity in serum is one of the diagnostic criteria of SLE. However, a minority of SLE patients may present with ANA negativity. We report a 70-year-old female who presented with massive edema and 10-gram/day proteinuria. Her serum antibodies for SLE were all negative and the renal biopsy showed a class V lupus nephritis. This case was unusual type of SLE due to multiple reasons namely the patient was an elderly woman, with isolated lupus nephritis and negative serology including ANA negativity.
  • Placeholder
    PublicationMetadata only
    Can incidental vascular calcifications at mammography be used as a screening biomarker for heart and kidney disease?
    (Sage, 2019) Covic, Adrian; A. Sag, Alan; Afsar, Barış; N/A; Erbil, Damla; Önal, Emine Meltem; Demirel, Çağrı; Dağel, Tuncay; Kanbay, Mehmet; Undergraduate Student; Undergraduate Student; Undergraduate Student; Doctor; Faculty Member; School of Medicine; School of Medicine; School of Medicine; N/A; School of Medicine; Koç University Hospital; N/A; N/A; N/A; N/A; 110580
    Mammography is a screening test with extensive international application and financial infrastructure promoting accessibility and affordability. Designed specifically to detect microcalcifications, mammography is powered to detect calcifications in vessel walls. Breast arterial calcifications (BAC) are one of the most common incidental findings documented by mammography. This review considers the literature regarding BAC in relation to cardiovascular disease (CVD) and its risk factors. The aim is to assess the possibility of using BAC as an early surrogate imaging biomarker of CVD.
  • Placeholder
    PublicationMetadata only
    GLP-1’s role in neuroprotection: a systematic review
    (Taylor & Francis Ltd, 2019) N/A; N/A; N/A; N/A; Erbil, Damla; Eren, Candan Yasemin; Demirel, Çağrı; Küçüker, Mehmet Utku; Solaroğlu, İhsan; Eser, Hale Yapıcı; Undergraduate Student; PhD Student; Undergraduate Student; Researcher; Faculty Member; Koç University Research Center for Translational Medicine (KUTTAM) / Koç Üniversitesi Translasyonel Tıp Araştırma Merkezi (KUTTAM); School of Medicine; Graduate School of Health Sciences; School of Medicine; School of Medicine; School of Medicine; N/A; N/A; N/A; N/A; 102059; 134359
    Glucagon-like peptide 1 (GLP-1) is a target for treatment of diabetes; however, its function in the brain is not well studied. In this systematic review, we aimed to analyze the neuroprotective role of GLP-1 and its defined mechanisms.Methods: We searched Web of Science' and Pubmed' to identify relevant studies using GLP-1 as the keyword. Two hundred and eighty-nine clinical and preclinical studies have been included. Data have been presented by grouping neurodegenerative, neurovascular and specific cell culture models.Results: Recent literature shows that GLP-1 and its agonists, DPP-4 inhibitors and combined GLP-1/GIP molecules are effective in partially or fully reversing the effects of neurotoxic compounds, neurovascular complications of diabetes, neuropathological changes related with Alzheimer's disease, Parkinson's disease or vascular occlusion. Possible mechanisms that provide neuroprotection are enhancing the viability of the neurons and restoring neurite outgrowth by increased neurotrophic factors, increasing subventricular zone progenitor cells, decreasing apoptosis, decreasing the level of pro-inflammatory factors, and strengthening blood-brain barrier.Conclusion: Based on the preclinical studies, GLP-1 modifying agents are promising targets for neuroprotection. On the other hand, the number of clinical studies that investigate GLP-1 as a treatment is low and further clinical trials are needed for a benchside to bedside translation of recent findings.